MiMedx Group, Inc. (NASDAQ: MDXG)

This investigation is for anyone who acquired securities in MiMedx Group, Inc. (NASDAQ: MDXG) from November 2, 2022 through December 29, 2023.

The Law Offices of Howard G. Smith believes that the Company and certain of its executives violated federal law. Specifically, the Law Offices of Howard G. Smith believes that the Company misled investors regarding its financial condition. More specifically, the Law Offices of Howard G. Smith believes that the Company misled investors by telling investors that its biologic, Axiofill, would not pose a significant risk to public health and therefore would not be subject to the normal FDA approval process, when, in fact, the Company knew that the drug would be subject to the normal approval process.

On December 29, 2023, after the market closed, MiMedx disclosed that it had received a warning letter from the U.S. Food and Drug Administration stating that the Company’s placental-derived tissue product, Axiofill, does not meet the requirements as a Section 361 product and is therefore subject to enforcement as a Section 351 product. On this news, the price of the Company’s stock dropped precipitously on unusually heavy trading volume.

The Law Offices of Howard G. Smith seeks to recover damages on behalf of class members. If you acquired securities in MiMedx Group, Inc. (NASDAQ: MDXG) from November 2, 2022 through December 29, 2023 you may join the lawsuit by submitting your information online, or you may call the Law Offices of Howard G. Smith and speak to Mr. Smith directly to learn how he can protect your rights.